AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Decousser, J.-W.
Right arrow Articles by Allouch, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Decousser, J.-W.
Right arrow Articles by Allouch, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2004, p. 3636-3639, Vol. 48, No. 9
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.9.3636-3639.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Invasive Streptococcus pneumoniae in France: Antimicrobial Resistance, Serotype, and Molecular Epidemiology Findings from a Monthly National Study in 2000 to 2002

Jean-Winoc Decousser,1* Patrick Pina,2 Florent Viguier,1 Franc Picot,1 Patrice Courvalin,3 Pierre Allouch,1 and the ColBVH Study Group{dagger}

Service d'Hygiène Hospitalière, Centre Hospitalier de Versailles André Mignot, Le Chesnay,1 Service de Médecine B, Hôpital de Plaisir Grignon,2 Unité des Agents Antibactériens, Institut Pasteur, Paris, France3

Received 3 December 2003/ Returned for modification 27 February 2004/ Accepted 1 May 2004

A study of 257 French invasive pneumococci isolated between 2000 and 2002 showed high rates of nonsusceptibility to penicillin and macrolides (50%), contrasting with a low frequency of resistance to amoxicillin or levofloxacin (<1%) and tolerance to vancomycin (0%). The genetic homogeneity of some serogroups, including serogroup 1, enhanced the risk of epidemiological changes.


* Corresponding author. Mailing address: Centre Hospitalier de Versailles André Mignot, Service d'Hygiène Hospitalière, 177 rue de Versailles, 78157 Le Chesnay Cedex, France. Phone: (33) 1 39 63 91 33. Fax: (33) 1 39 63 93 12. E-mail: JWDECOUSSER{at}ch-versailles.fr.

{dagger} Contributing members of the ColBVH Study Group are listed in Acknowledgments.


Antimicrobial Agents and Chemotherapy, September 2004, p. 3636-3639, Vol. 48, No. 9
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.9.3636-3639.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.